Lite Strategy
Lite Strategy

Financials • Lite Strategy

LITS

Lite Strategy Inc is focused on the clinical development of novel therapies for cancer. The company's portfolio of drug candidates includes voruciclib, an oral cyclin-dependent kinase 9 (CDK9) inhibitor and zandelisib, an oral, once-daily, selective PI3K inhibitor. It is a clinical-stage pharmaceutical company committed to the development of novel and differentiated cancer therapies intended to improve outcomes for patients.

Complete and updated financials table with all primary indicators: Net Income, Revenue, EBITDA, Margin, ROE, Dividends

Year
06/2016
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
06/2017
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
06/2018
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
06/2019
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
06/2020
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
$1,345
06/2021
35
-60
-12
L
L
49
L
-153
-
-42
-1
3
-43
0
0
-
-
06/2022
41
-75
-12
L
L
52
L
-153
-
-57
-0
49
-58
-0
0
-
-
06/2023
49
-36
-12
L
L
25
L
-101
-
-56
-0
-0
-56
-0
0
-
-
06/2024
65
15
01
27%
2.7
33
54%
-38
-
-53
-0
-12
-53
0
-12
66%
-
06/2025
0
-17
-12
0%
L
17
L
-18
-
-21
0
0
-21
0
0
-
-

To see all financials—including updated, you must be Premium.